Literature DB >> 15650618

Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients.

Beryl Silkey1, Sheldon H Preskorn, Amanda Golbeck, Rozina Shah, Melissa Neff, Teresa L Jones, Joe Choi.   

Abstract

CONTEXT: A previous study, described in Part I of this report, found that 71% of a sample of 5,003 general outpatients in the Veterans Affairs healthcare system were receiving a unique drug regimen (i.e., total specific drug entities regardless of dose, formulation, or administration schedule). The simplest regimens contained only one drug, while the most complex regimens exceeded 20 different drugs. The purpose of the present study was to determine if patients receiving a specific therapeutic class of medications (e.g., antidepressants) have more homogeneous drug regimens.
OBJECTIVE: to examine the extent and complexity of multiple medication use in younger and older adult outpatients receiving antidepressants compared with those not receiving antidepressants. The study focused on drugs that act systemically or gastrointestinally and hence have the potential to interact. DESIGN, SETTING, AND PARTICIPANTS: Two subsets of stratified random samples of outpatients selected from prescription databases of U.S. Veterans Integrated Service Network 15. The first group involved 1,991 patients deemed to be on antidepressants (AD patients): 891 aged < 60 years and 1,100 aged > or = 60 years. The second group involved 3,732 patients who had received no antidepressants within the previous 365 days but who had a supply of at least one other current prescription (NoAD patients): 1,195 aged < 60 years and 2,535 aged > or = 60 years; 2 missing age information. MAIN OUTCOME MEASURES: number of drugs, frequency of drug regimens, level of multiple medication use including and excluding antidepressants.
RESULTS: Younger AD patients received 3 more drugs than younger NoAD patients. 23.6% of younger AD patients, versus 5.9% of younger NoAD patients, received > or = 8 drugs. Older AD patients received 2 more drugs than older NoAD patients. 37.6% of older AD patients, versus 12.8% of older NoAD patients, received > or = 8 drugs. In both the AD and NoAD groups, 62%-96% of patients of all ages were receiving unique drug regimens. Each drug regimen containing 2 or more drugs occurred in fewer than 1% of patients.
CONCLUSIONS: AD patients were receiving more complex drug regimens and had a higher frequency of unique drug regimens than NoAD patients, even when the results were adjusted for age group and number of prescribers. The high prevalence of unique drug combinations in all patient groups in this study indicates that clinicians in this system have only limited experience with the total effects of all of the medications their patients are receiving and thus cannot rely on experience to guard against adverse multi-drug interactions. This fact is a particular concern with psychiatric medications because adverse DDIs involving these medications can mimic psychiatric symptoms and may therefore be more difficult to detect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650618     DOI: 10.1097/00131746-200501000-00003

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  8 in total

1.  Evaluation of Potential Drug-Drug Interactions with Antidepressants in Two Tertiary Care Hospitals.

Authors:  Muhammad Salman Rafi; Syed Baqir Shyum Naqvi; Muhammad Umair Khan; Muhammad Fayyaz; Nida Ashraf; Maqsood Ahmed Khan; Akram Ahmad; Sameer Dhingra
Journal:  J Clin Diagn Res       Date:  2015-07-01

2.  Acquired Stuttering in Veterans of the Wars in Iraq and Afghanistan: The Role of Traumatic Brain Injury, Post-Traumatic Stress Disorder, and Medications.

Authors:  Rocío S Norman; Carlos A Jaramillo; Blessen C Eapen; Megan E Amuan; Mary Jo Pugh
Journal:  Mil Med       Date:  2018-11-01       Impact factor: 1.437

3.  How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.

Authors:  Matthew Macaluso; Alice I Nichols; Sheldon H Preskorn
Journal:  Prim Care Companion CNS Disord       Date:  2015-03-19

Review 4.  Interventions to improve the appropriate use of polypharmacy for older people.

Authors:  Audrey Rankin; Cathal A Cadogan; Susan M Patterson; Ngaire Kerse; Chris R Cardwell; Marie C Bradley; Cristin Ryan; Carmel Hughes
Journal:  Cochrane Database Syst Rev       Date:  2018-09-03

5.  Prediction of individual response to antidepressants and antipsychotics: an integrated concept.

Authors:  Sheldon H Preskorn
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

Review 6.  Potential Clinical and Economic Impact of Switching Branded Medications to Generics.

Authors:  Robert J Straka; Denis J Keohane; Larry Z Liu
Journal:  Am J Ther       Date:  2017-05       Impact factor: 2.688

7.  Determinants and consequences of polypharmacy in patients with a depressive disorder in later life.

Authors:  Carlijn Wiersema; Richard C Oude Voshaar; Rob H S van den Brink; Hans Wouters; Peter Verhaak; Hannie C Comijs; Hans W Jeuring
Journal:  Acta Psychiatr Scand       Date:  2022-04-29       Impact factor: 7.734

8.  Why Are Patients With COVID-19 at Risk for Drug-Drug Interactions?

Authors:  Sheldon H Preskorn; Syeda Quadri
Journal:  J Psychiatr Pract       Date:  2020-11       Impact factor: 1.841

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.